
    
      Patients with locally advanced transitional cell bladder cancer receive 3 cycles of
      neoadjuvant gemcitabine/cisplatin before radical cystectomy.

      Patients with histologically confirmed clinical stage T2-T4a, N0-2 bladder cancer are going
      to be included. After CT scan of the thorax and abdomen plus MRI of the pelvis patient
      receive chemotherapy.

      Pathologic response rate will be assessed after surgery by the institutional pathologic
      review. Safety is going to be assessed according to the National Cancer Institute Common
      Toxicity Criteria (CTC,version 3.0).
    
  